Your browser doesn't support javascript.
loading
Relevance of the MHC region for breast cancer susceptibility in Asians.
Ho, Peh Joo; Khng, Alexis Jiaying; Tan, Benita Kiat-Tee; Tan, Ern Yu; Tan, Su-Ming; Tan, Veronique Kiak Mien; Lim, Geok Hoon; Aronson, Kristan J; Chan, Tsun L; Choi, Ji-Yeob; Dennis, Joe; Ho, Weang-Kee; Hou, Ming-Feng; Ito, Hidemi; Iwasaki, Motoki; John, Esther M; Kang, Daehee; Kim, Sung-Won; Kurian, Allison W; Kwong, Ava; Lophatananon, Artitaya; Matsuo, Keitaro; Mohd-Taib, Nur Aishah; Muir, Kenneth; Murphy, Rachel A; Park, Sue K; Shen, Chen-Yang; Shu, Xiao-Ou; Teo, Soo Hwang; Wang, Qin; Yamaji, Taiki; Zheng, Wei; Bolla, Manjeet K; Dunning, Alison M; Easton, Douglas F; Pharoah, Paul D P; Hartman, Mikael; Li, Jingmei.
Afiliación
  • Ho PJ; Women's Health and Genetics, Genome Institute of Singapore, 60 Biopolis Street, Genome, #02-01, Singapore, 138672, Singapore.
  • Khng AJ; Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore, 119077, Singapore.
  • Tan BK; Department of Surgery, National University Health System, Singapore, 119228, Singapore.
  • Tan EY; Women's Health and Genetics, Genome Institute of Singapore, 60 Biopolis Street, Genome, #02-01, Singapore, 138672, Singapore.
  • Tan SM; Department of Breast Surgery, Singapore General Hospital, Singapore, Singapore.
  • Tan VKM; Division of Surgery and Surgical Oncology, National Cancer Centre Singapore, Singapore, Singapore.
  • Lim GH; Department of General Surgery, Sengkang General Hospital, Singapore, Singapore.
  • Aronson KJ; Department of General Surgery, Tan Tock Seng Hospital, Singapore, 308433, Singapore.
  • Chan TL; Lee Kong Chian School of Medicine, Singapore, Singapore.
  • Choi JY; Institute of Molecular and Cell Biology, Singapore, Singapore.
  • Dennis J; Division of Breast Surgery, Changi General Hospital, Singapore, Singapore.
  • Ho WK; Department of Breast Surgery, Singapore General Hospital, Singapore, Singapore.
  • Hou MF; Division of Surgery and Surgical Oncology, National Cancer Centre Singapore, Singapore, Singapore.
  • Ito H; KK Breast Department, KK Women's and Children's Hospital, Singapore, 229899, Singapore.
  • Iwasaki M; Department of Public Health Sciences, and Cancer Research Institute, Queen's University, Kingston, ON, K7L 3N6, Canada.
  • John EM; Hong Kong Hereditary Breast Cancer Family Registry, Hong Kong, Hong Kong.
  • Kang D; Department of Molecular Pathology, Hong Kong Sanatorium and Hospital, Hong Kong, Hong Kong.
  • Kim SW; Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, 03080, Korea.
  • Kurian AW; Cancer Research Institute, Seoul National University, Seoul, 03080, Korea.
  • Kwong A; Institute of Health Policy and Management, Seoul National University Medical Research Center, Seoul, 03080, Korea.
  • Lophatananon A; Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, CB1 8RN, UK.
  • Matsuo K; Department of Mathematical Sciences, Faculty of Science and Engineering, University of Nottingham Malaysia Campus, 43500, Semenyih, Selangor, Malaysia.
  • Mohd-Taib NA; Breast Cancer Research Programme, Cancer Research Malaysia, 47500, Subang Jaya, Selangor, Malaysia.
  • Muir K; Department of Surgery, Kaohsiung Municipal Hsiao-Kang Hospital, Kao-hsiung, 812, Taiwan.
  • Murphy RA; Division of Cancer Information and Control, Aichi Cancer Center Research Institute, Nagoya, 464-8681, Japan.
  • Park SK; Division of Cancer Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, 466-8550, Japan.
  • Shen CY; Division of Epidemiology, Center for Public Health Sciences, National Cancer Center, Tokyo, 104-0045, Japan.
  • Shu XO; Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA, 94305, USA.
  • Teo SH; Department of Medicine, Division of Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, 94304, USA.
  • Wang Q; Cancer Research Institute, Seoul National University, Seoul, 03080, Korea.
  • Yamaji T; Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, 03080, Korea.
  • Zheng W; Department of Surgery, Daerim Saint Mary's Hospital, Seoul, 07442, Korea.
  • Bolla MK; Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA, 94305, USA.
  • Dunning AM; Department of Medicine, Division of Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, 94304, USA.
  • Easton DF; Hong Kong Hereditary Breast Cancer Family Registry, Hong Kong, Hong Kong.
  • Pharoah PDP; Department of Surgery, The University of Hong Kong, Hong Kong, Hong Kong.
  • Hartman M; Department of Surgery and Cancer Genetics Center, Hong Kong Sanatorium and Hospital, Hong Kong, Hong Kong.
  • Li J; Division of Population Health, Health Services Research and Primary Care, School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, M13 9PL, UK.
Breast Cancer ; 29(5): 869-879, 2022 Sep.
Article en En | MEDLINE | ID: mdl-35543923
ABSTRACT

BACKGROUND:

Human leukocyte antigen (HLA) genes play critical roles in immune surveillance, an important defence against tumors. Imputing HLA genotypes from existing single-nucleotide polymorphism datasets is low-cost and efficient. We investigate the relevance of the major histocompatibility complex region in breast cancer susceptibility, using imputed class I and II HLA alleles, in 25,484 women of Asian ancestry.

METHODS:

A total of 12,901 breast cancer cases and 12,583 controls from 12 case-control studies were included in our pooled analysis. HLA imputation was performed using SNP2HLA on 10,886 quality-controlled variants within the 15-55 Mb region on chromosome 6. HLA alleles (n = 175) with info scores greater than 0.8 and frequencies greater than 0.01 were included (resolution at two-digit level 71; four-digit level 104). We studied the associations between HLA alleles and breast cancer risk using logistic regression, adjusting for population structure and age. Associations between HLA alleles and the risk of subtypes of breast cancer (ER-positive, ER-negative, HER2-positive, HER2-negative, early-stage, and late-stage) were examined.

RESULTS:

We did not observe associations between any HLA allele and breast cancer risk at P < 5e-8; the smallest p value was observed for HLA-C*1203 (OR = 1.29, P = 1.08e-3). Ninety-five percent of the effect sizes (OR) observed were between 0.90 and 1.23. Similar results were observed when different subtypes of breast cancer were studied (95% of ORs were between 0.85 and 1.18).

CONCLUSIONS:

No imputed HLA allele was associated with breast cancer risk in our large Asian study. Direct measurement of HLA gene expressions may be required to further explore the associations between HLA genes and breast cancer risk.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Antígenos HLA Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Breast Cancer Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Singapur

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Antígenos HLA Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Breast Cancer Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Singapur